show help

Harrigan PR

Author page

This page provides a summary of the entries in Polbase associated with this author.

The publication history graph presents the number of publications in Polbase by this author over time.

The polymerase chart indicates which polymerases this author has published on.

Polbase automatically discovers many polymerase papers as they are published. Some relevant papers are not included because the algorithm is designed to reduce background. Please contribute to polbase by adding your missing DNA polymerase papers.

Help icons:

The show help symbol in the upper-right corner of the page links to this help text. The question mark icon is used everywhere to indicate that help is available.

Missing references?


Title Authors Year Journal
Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. Harrigan PR 2008 The Journal of biological chemistry
Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naive individuals in a Western setting. Harrigan PR 2007 HIV Med
A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Harrigan PR 2007 Clin Infect Dis
Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. Harrigan PR 2007 Infect Genet Evol
Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide. Harrigan PR 2007 Antiviral Res
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients. Harrigan PR 2007 Aids
Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Harrigan PR 2007 Antivir Ther
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. Harrigan PR 2007 PLoS Med
A 21-base pair insertion/duplication at codon 69 of the HIV type 1 reverse transcriptase in a patient undergoing multiple nucleoside therapy. Harrigan PR 2007 AIDS Res Hum Retroviruses
Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. Harrigan PR 2007 J Infect Dis
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. Harrigan PR 2007 PLoS Pathog
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. Harrigan PR 2007 Aids
Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. Harrigan PR 2007 Aids
Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. Harrigan PR 2007 PLoS Comput Biol
Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. Harrigan PR 2007 J Clin Microbiol
HIV-1 drug resistance surveillance using dried whole blood spots. Harrigan PR 2007 Antivir Ther
Transmission of drug-resistant HIV-1 from an infected individual to a caregiver. Harrigan PR 2007 Antivir Ther
A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. Harrigan PR 2002 Journal of virology
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. Harrigan PR 2000 J Infect Dis
Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine (dOTC). Harrigan PR 1999 Antiviral therapy
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. Harrigan PR 1996 J Virol
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Harrigan PR 1995 Science

Using Polbase tables:


Tables may be sorted by clicking on any of the column titles. A second click reverses the sort order. <Ctrl> + click on the column titles to sort by more than one column (e.g. family then name).


It is also possible to filter the table by typing into the search box above the table. This will instantly hide lines from the table that do not contain your search text.